Lataa...
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab (D) to RVd (D-RVd) in transplant-eligible NDMM patients w...
Tallennettuna:
| Julkaisussa: | Blood |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7441167/ https://ncbi.nlm.nih.gov/pubmed/32325490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005288 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|